Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Pembrolizumab, sold under the brand name Keytruda, is a humanized monoclonal antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy to treat many types of cancer. It is administered by slow intravenous injection.
History, Community, Culture & Applications
Explore the main themes, entities and connections around Pembrolizumab. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
metastatic cancer treatment fda approved us pd-l1 advanced carcinoma cell people chemotherapy tumors trial combination adults drug lung locally participants
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Pembrolizumab | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Pembrolizumab | ATC code | L01FF02 (WHO) | 1.00 | infobox |
| Pembrolizumab | CAS Number | 1374853-91-4 | 1.00 | infobox |
| Pembrolizumab | ChEMBL | ChEMBL3137343 | 1.00 | infobox |
| Pembrolizumab | ChemSpider | none | 1.00 | infobox |
| Pembrolizumab | Drug class | Antineoplastic | 1.00 | infobox |
| Pembrolizumab | DrugBank | DB09037 | 1.00 | infobox |
| Pembrolizumab | ECHA InfoCard | 100.234.370 | 1.00 | infobox |
| Pembrolizumab | Formula | C6534H10004N1716O2036S46 | 1.00 | infobox |
| Pembrolizumab | KEGG | D10574 | 1.00 | infobox |
| Pembrolizumab | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Pembrolizumab | Legal status | CA: ℞-only / Schedule D | 1.00 | infobox |
| Pembrolizumab | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Pembrolizumab | Legal status | US: ℞-only | 1.00 | infobox |
| Pembrolizumab | Legal status | EU: Rx-only | 1.00 | infobox |
| Pembrolizumab | Legal status | In general: ℞ (Prescription only) | 1.00 | infobox |
| Pembrolizumab | License data | US DailyMed: Pembrolizumab | 1.00 | infobox |
| Pembrolizumab | MedlinePlus | a614048 | 1.00 | infobox |
| Pembrolizumab | Molar mass | 146648.64 g·mol−1 | 1.00 | infobox |
| Pembrolizumab | Other names | MK-3475, lambrolizumab | 1.00 | infobox |
| Pembrolizumab | Pregnancy category | AU: D | 1.00 | infobox |
| Pembrolizumab | Routes of administration | Intravenous | 1.00 | infobox |
| Pembrolizumab | Source | Humanized (from mouse) | 1.00 | infobox |
| Pembrolizumab | Target | PD-1 | 1.00 | infobox |
| Pembrolizumab | Trade names | Keytruda | 1.00 | infobox |
| Pembrolizumab | Type | Whole antibody | 1.00 | infobox |
| Pembrolizumab | UNII | DPT0O3T46P | 1.00 | infobox |
| Pembrolizumab | is a | so-called tissue-agnostic drug.In the European Union | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.